Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis

Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in... Despite significant advances in our ability to treat cancer, cytotoxic chemotherapy continues to be the mainstay treatment for many solid tumours. Chemotherapy is commonly associated with a raft of largely manageable adverse events; however, gastrointestinal (GI) toxicity (also termed mucositis) remains a significant challenge with little in the way of preventative and therapeutic options. The inability to manage GI complications likely reflects our incomplete understanding of its aetiology and the idiosyncrasies of each chemotherapeutic agent. This review highlights aims to provide a narrative for the involvement of Toll-like receptor (TLR4) in the development of chemotherapy-induced GI mucositis, an already emerging theme within this field. Particular focus will be placed upon the signalling interaction between TLR4 and interleukin (IL)-6. This parallels recent preclinical findings showing that TLR4 knockout mice, which are protected from developing severe GI mucositis, completely lack an IL-6 response. As such, we suggest that this signalling pathway presents as a novel mechanism with potential for therapeutic intervention. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis

Download PDF
7 pages

Loading next page...
 
/lp/springer_journal/role-of-toll-like-receptor-4-tlr4-mediated-interleukin-6-il-6-KSWtKXDOYy
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3605-9
Publisher site
See Article on Publisher Site

Abstract

Despite significant advances in our ability to treat cancer, cytotoxic chemotherapy continues to be the mainstay treatment for many solid tumours. Chemotherapy is commonly associated with a raft of largely manageable adverse events; however, gastrointestinal (GI) toxicity (also termed mucositis) remains a significant challenge with little in the way of preventative and therapeutic options. The inability to manage GI complications likely reflects our incomplete understanding of its aetiology and the idiosyncrasies of each chemotherapeutic agent. This review highlights aims to provide a narrative for the involvement of Toll-like receptor (TLR4) in the development of chemotherapy-induced GI mucositis, an already emerging theme within this field. Particular focus will be placed upon the signalling interaction between TLR4 and interleukin (IL)-6. This parallels recent preclinical findings showing that TLR4 knockout mice, which are protected from developing severe GI mucositis, completely lack an IL-6 response. As such, we suggest that this signalling pathway presents as a novel mechanism with potential for therapeutic intervention.

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: May 29, 2018

References

  • What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?
    Gibson, RJ; Bowen, JM; Coller, JK
  • The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis
    Elting, LS
  • Effect of high-dose chemotherapy on intestinal permeability in humans
    Keefe, DM
  • TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity?
    Wardill, HR
  • Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity
    Cario, E
  • Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA
    Kelly, D
  • Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer
    Eyking, A
  • TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice
    Spiller, S
  • Pathobiology of oral mucositis: novel insights and opportunities
    Sonis, ST
  • Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis
    Logan, RM
  • Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens
    Velikova, T
  • The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs
    Logan, RM
  • Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms
    Wardill, HR
  • Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines
    Peterson, DE
  • MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
    Lalla, RV
  • Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries
    Vouk, K
  • The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue
    Carlotto, A
  • Abstracts of the MASCC/ISOO 2017 annual meeting
    White, T; De Abreu Lourenco, R; Kenny, P; Lehane, L; D'Abrew, N
  • The pathobiology of mucositis
    Sonis, ST
  • Intestinal stem cell injury and protection during cancer therapy
    Yu, J
  • Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy
    Logan, RM
  • Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity
    Wardill, HR
  • TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea
    Wardill, HR
  • Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer
    Wardill, HR
  • Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant
    Blijlevens, NM; Donnelly, JP; Pauw, BE
  • Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans
    Keefe, D
  • A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice
    Pereira, VB
  • Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways
    Kaczmarek, A
  • IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice
    Guabiraba, R
  • Microbial translocation contribute to febrile episodes in adults with chemotherapy-induced neutropenia
    Wong, M
  • Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study
    Wisplinghoff, H
  • Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors
    Thorpe, DW; Stringer, AM; Gibson, RJ
  • The microbiome and innate immunity
    Thaiss, CA
  • Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice
    Pedroso, SH
  • Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis
    Stringer, AM
  • Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats
    Stringer, AM
  • Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile
    Stringer, AM
  • 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation
    Montassier, E
  • Chemotherapy-driven dysbiosis in the intestinal microbiome
    Montassier, E
  • Intestinal microflora and digestive toxicity of irinotecan in mice
    Brandi, G
  • Administration of probiotic mixture DM#1 ameliorated 5-fluorouracil-induced intestinal mucositis and dysbiosis in rats
    Tang, Y
  • Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study
    Osterlund, P
  • Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients
    Motoori, M
  • VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss
    Bowen, JM
  • The efficacy and safety of probiotics in people with cancer: a systematic review
    Redman, MG; Ward, EJ; Phillips, RS
  • The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis
    Wang, YH
  • Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis
    Wardill, HR
  • Toll-like receptor 4 (tlr4)-mediated tight junction disruption and dysregulated ion secretion are key drivers of irinotecan-induced diarrhoea
    Wardill, H
  • IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3
    Greenhill, CJ
  • Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis
    Fukata, M
  • TLR signaling modulates side effects of anticancer therapy in the small intestine
    Frank, M
  • Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis
    Hamada, K; Kakigawa, N; Sekine, S; Shitara, Y; Horie, T
  • Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs
    Logan, RM
  • Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report
    Coller, JK
  • Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism
    Riehl, T
  • The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer
    Naugler, WE; Karin, M
  • Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer
    Karin, M; Lawrence, T; Nizet, V
  • Proinflammatory cytokines during the initial phase of oral mucositis in patients with acute lymphoblastic leukaemia
    Morales-Rojas, T
  • Helicobacter pylori protein JHP0290 binds to multiple cell types and induces macrophage apoptosis via tumor necrosis factor (TNF)-dependent and independent pathways
    Pathak, SK
  • The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5
    Hayashi, F
  • Involvement of TLR2 and TLR4 in inflammatory immune responses induced by fine and coarse ambient air particulate matter
    Shoenfelt, J
  • Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology
    Demacker, PN